At the time of his diagnosis, Dale Atkinson was a father of two living in Burghfield Common near Reading. He recalled that he experienced heartburn and acid reflux for many years before his cancer diagnosis. He visited his general practitioner in 2019 due to acid reflux and was prescribed omeprazole; he said he was initially reassured that it was nothing serious. However, Atkinson felt that as his symptoms progressed, he did not receive adequate support from his doctors. By 2023 to 2024, his condition had deteriorated significantly, with new problems including pain after eating, difficulty swallowing, and substantial weight loss. The NHS warns that persistent difficulty swallowing, heartburn, indigestion, a cough, and a hoarse voice can be signs of oesophageal cancer and should prompt a medical evaluation, especially if they persist or worsen. Medical experts note that oesophageal adenocarcinoma, the type of cancer Atkinson later developed, is strongly associated with chronic gastroesophageal reflux disease (GERD) and Barrett’s oesophagus, a precancerous condition where the lining of the oesophagus changes.
Atkinson’s cancer was eventually identified as stage four oesophageal adenocarcinoma that had spread to multiple lymph nodes, including those around the aorta. Doctors told him the disease was incurable and inoperable. He was offered palliative treatment and given a prognosis of just 11.5 months. During this time, his partner Ana was diagnosed with lung cancer and underwent surgery to remove part of her lung, a lobectomy. Facing a bleak outlook, Atkinson took an unconventional step: he assembled a personalized treatment team that combined standard NHS oncology care with additional strategies. According to Atkinson, he incorporated metabolic therapies, nutritional interventions, and repurposed drugs—medications originally developed for other conditions—into his regimen, aiming to target his cancer from multiple angles. While such off-label approaches are not yet standard, some oncologists are investigating whether repurposed drugs like metformin and statins, combined with dietary changes, can improve outcomes. The specifics of his tailored protocol have not been publicly disclosed, but his approach reflects a growing movement among patients to seek integrative cancer care.
The CARv3-TEAM-E therapy combines two forms of therapy to treat glioblastoma more broadly, as tumor cells vary within the same tumor.
Recent advances in cancer treatment highlight why some patients are exploring beyond traditional protocols. A clinical study reported that 59% of patients with high-risk bowel cancer had no detectable cancer after nine weeks of immunotherapy, a result that challenges conventional treatment pathways. The trial used a drug that releases the immune system to fight cancer, and researchers are now exploring similar strategies for other tumor types. In another remarkable case, Ben Trotman was diagnosed with glioblastoma, an aggressive brain cancer, in 2022 when he was 40 years old. More than two years later, according to his medical team, his scans show no signs of the disease following a combination of ipilimumab, radiation, and chemotherapy. Dr. Paul Mulholland, involved in his care, noted that it is exceptionally rare for a glioblastoma patient to have a clear scan, particularly when no follow-up surgery was performed to remove the tumor that was once visible. Trotman had been the sole participant in a glioblastoma clinical trial that ended early due to low enrollment. Now, a new University College London-sponsored trial is set to recruit 16 patients with newly diagnosed glioblastoma to receive ipilimumab before standard treatments, potentially expanding access to this promising therapy.
Glioblastoma research has also seen exciting developments with CAR T-cell therapy. CAR-T therapies work by modifying a patient’s own immune cells to recognize and attack cancer, but glioblastoma has proven difficult to treat because of its ability to evade the immune system and the protective blood-brain barrier. A Phase 1 trial of CARv3-TEAM-E, a next-generation therapy, produced dramatic tumor reductions in the first three patients with recurrent glioblastoma, with one patient experiencing near-complete regression. Bryan Choi, a neurosurgeon at Massachusetts General Hospital, explained that the therapy is designed to attack glioblastoma cells more comprehensively by combining two therapeutic approaches, addressing the diversity of cancer cells within a single tumor. The technology was developed in Massachusetts General Hospital laboratories and moved into patients within just five years. However, researchers caution that tumor progression was later seen in these initial patients, and efforts are underway to make responses more durable.
A clear scan with glioblastoma is very unusual, especially without follow-up surgery to remove the initially visible tumor.
Another patient, identified as Brian, a 40-year-old man, was diagnosed with limited-stage small cell lung cancer after a workplace injury prompted a chest X-ray that revealed a mass, according to media reports. This highlights how cancer can sometimes be discovered incidentally during unrelated medical evaluations. Brian said he had experienced heartburn for years and was repeatedly told by physicians that it was GERD, not cancer. The misdiagnosis of GERD is common, as heartburn can be a symptom of several conditions, but in some cases it may mask a more serious underlying illness. He described his treatment plan as including three consecutive days of chemotherapy, followed by a 21-day break, along with radiation therapy delivered twice daily, five days per week. The American Cancer Society defines limited-stage small cell lung cancer as disease confined to one side of the chest that can be encompassed within a single radiation field. The organization projects that more than 2 million new cancer cases will be diagnosed in the United States in 2025.
The experiences of Atkinson, Brian, and others underscore the importance of not dismissing persistent symptoms like heartburn and the potential value of individualized treatment strategies. For Atkinson, building a bespoke medical team offered a measure of control in a situation defined by uncertainty. While the effectiveness of his specific approach has not been proven, his story, along with emerging therapies and clinical trials, provides hope to patients facing dire prognoses. While the scientific community continues to debate the role of off-label and complementary therapies, patient-led initiatives like Atkinson’s underscore the demand for more personalized and holistic cancer care models.